Dopamine agonists in animal models of Parkinson's disease

a systematic review and meta-analysis

Evelien D.M. Rooke, Hanna M. Vesterinen, Emily S. Sena, Kieren J. Egan, Malcolm R. Macleod

Research output: Contribution to journalReview article

48 Citations (Scopus)

Abstract

Background: Parkinson's disease (PD) can be a severely disabling condition in spite of therapies currently available. Systematic review and meta-analysis can provide an overview of a field of research and identify potential sources of bias and limits to efficacy. In this study we use these tools to describe the reported efficacy of dopamine agonists in animal models of PD. Methods: Publications were identified by electronic searching of three online databases. Data were extracted for neurobehavioural outcome, for study design and for the reporting of measures to avoid bias. Standardised mean difference meta-analysis was used to provide summary estimates of efficacy, with the effects of study quality and study design explored using stratified meta-analysis. Results: 253 publications reported the use of a dopamine agonist in an animal model of PD; of these 121 reported data suitable for inclusion in meta-analysis. 47 interventions were tested in 601 experiments using 4181 animals. Overall, neurobehavioural outcome was improved by 1.08 standard deviations (SD; 95% Confidence Interval (CI) 0.97-1.19). Reporting of measures to reduce bias was low and publications which reported the blinded assessment of outcome had significantly smaller effect sizes (0.85, 95% CI 0.64 to 1.07) than those which did not (1.18, 95% CI 1.05 to 1.31, p < 0.005). Conclusions: While dopamine agonists do appear to have efficacy in animal models of PD the low prevalence of reporting of measures to avoid bias is of concern. Systematic review of individual interventions may be helpful in the design of future preclinical and clinical trials.

Original languageEnglish
Pages (from-to)313-320
Number of pages8
JournalParkinsonism and Related Disorders
Volume17
Issue number5
Early online date4 Mar 2011
DOIs
Publication statusPublished - 30 Jun 2011

Fingerprint

Dopamine Agonists
Parkinson Disease
Meta-Analysis
Animal Models
Publications
Confidence Intervals
Outcome Assessment (Health Care)
Clinical Trials
Databases
Research
Therapeutics

Keywords

  • animal model
  • dopamine agonist
  • meta-analysis
  • study quality
  • systematic review

Cite this

Rooke, Evelien D.M. ; Vesterinen, Hanna M. ; Sena, Emily S. ; Egan, Kieren J. ; Macleod, Malcolm R. / Dopamine agonists in animal models of Parkinson's disease : a systematic review and meta-analysis. In: Parkinsonism and Related Disorders . 2011 ; Vol. 17, No. 5. pp. 313-320.
@article{f6f179beefdd459c832ee40bb6fcc7ce,
title = "Dopamine agonists in animal models of Parkinson's disease: a systematic review and meta-analysis",
abstract = "Background: Parkinson's disease (PD) can be a severely disabling condition in spite of therapies currently available. Systematic review and meta-analysis can provide an overview of a field of research and identify potential sources of bias and limits to efficacy. In this study we use these tools to describe the reported efficacy of dopamine agonists in animal models of PD. Methods: Publications were identified by electronic searching of three online databases. Data were extracted for neurobehavioural outcome, for study design and for the reporting of measures to avoid bias. Standardised mean difference meta-analysis was used to provide summary estimates of efficacy, with the effects of study quality and study design explored using stratified meta-analysis. Results: 253 publications reported the use of a dopamine agonist in an animal model of PD; of these 121 reported data suitable for inclusion in meta-analysis. 47 interventions were tested in 601 experiments using 4181 animals. Overall, neurobehavioural outcome was improved by 1.08 standard deviations (SD; 95{\%} Confidence Interval (CI) 0.97-1.19). Reporting of measures to reduce bias was low and publications which reported the blinded assessment of outcome had significantly smaller effect sizes (0.85, 95{\%} CI 0.64 to 1.07) than those which did not (1.18, 95{\%} CI 1.05 to 1.31, p < 0.005). Conclusions: While dopamine agonists do appear to have efficacy in animal models of PD the low prevalence of reporting of measures to avoid bias is of concern. Systematic review of individual interventions may be helpful in the design of future preclinical and clinical trials.",
keywords = "animal model, dopamine agonist, meta-analysis, study quality, systematic review",
author = "Rooke, {Evelien D.M.} and Vesterinen, {Hanna M.} and Sena, {Emily S.} and Egan, {Kieren J.} and Macleod, {Malcolm R.}",
year = "2011",
month = "6",
day = "30",
doi = "10.1016/j.parkreldis.2011.02.010",
language = "English",
volume = "17",
pages = "313--320",
journal = "Parkinsonism and Related Disorders",
issn = "1353-8020",
number = "5",

}

Dopamine agonists in animal models of Parkinson's disease : a systematic review and meta-analysis. / Rooke, Evelien D.M.; Vesterinen, Hanna M.; Sena, Emily S.; Egan, Kieren J.; Macleod, Malcolm R.

In: Parkinsonism and Related Disorders , Vol. 17, No. 5, 30.06.2011, p. 313-320.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Dopamine agonists in animal models of Parkinson's disease

T2 - a systematic review and meta-analysis

AU - Rooke, Evelien D.M.

AU - Vesterinen, Hanna M.

AU - Sena, Emily S.

AU - Egan, Kieren J.

AU - Macleod, Malcolm R.

PY - 2011/6/30

Y1 - 2011/6/30

N2 - Background: Parkinson's disease (PD) can be a severely disabling condition in spite of therapies currently available. Systematic review and meta-analysis can provide an overview of a field of research and identify potential sources of bias and limits to efficacy. In this study we use these tools to describe the reported efficacy of dopamine agonists in animal models of PD. Methods: Publications were identified by electronic searching of three online databases. Data were extracted for neurobehavioural outcome, for study design and for the reporting of measures to avoid bias. Standardised mean difference meta-analysis was used to provide summary estimates of efficacy, with the effects of study quality and study design explored using stratified meta-analysis. Results: 253 publications reported the use of a dopamine agonist in an animal model of PD; of these 121 reported data suitable for inclusion in meta-analysis. 47 interventions were tested in 601 experiments using 4181 animals. Overall, neurobehavioural outcome was improved by 1.08 standard deviations (SD; 95% Confidence Interval (CI) 0.97-1.19). Reporting of measures to reduce bias was low and publications which reported the blinded assessment of outcome had significantly smaller effect sizes (0.85, 95% CI 0.64 to 1.07) than those which did not (1.18, 95% CI 1.05 to 1.31, p < 0.005). Conclusions: While dopamine agonists do appear to have efficacy in animal models of PD the low prevalence of reporting of measures to avoid bias is of concern. Systematic review of individual interventions may be helpful in the design of future preclinical and clinical trials.

AB - Background: Parkinson's disease (PD) can be a severely disabling condition in spite of therapies currently available. Systematic review and meta-analysis can provide an overview of a field of research and identify potential sources of bias and limits to efficacy. In this study we use these tools to describe the reported efficacy of dopamine agonists in animal models of PD. Methods: Publications were identified by electronic searching of three online databases. Data were extracted for neurobehavioural outcome, for study design and for the reporting of measures to avoid bias. Standardised mean difference meta-analysis was used to provide summary estimates of efficacy, with the effects of study quality and study design explored using stratified meta-analysis. Results: 253 publications reported the use of a dopamine agonist in an animal model of PD; of these 121 reported data suitable for inclusion in meta-analysis. 47 interventions were tested in 601 experiments using 4181 animals. Overall, neurobehavioural outcome was improved by 1.08 standard deviations (SD; 95% Confidence Interval (CI) 0.97-1.19). Reporting of measures to reduce bias was low and publications which reported the blinded assessment of outcome had significantly smaller effect sizes (0.85, 95% CI 0.64 to 1.07) than those which did not (1.18, 95% CI 1.05 to 1.31, p < 0.005). Conclusions: While dopamine agonists do appear to have efficacy in animal models of PD the low prevalence of reporting of measures to avoid bias is of concern. Systematic review of individual interventions may be helpful in the design of future preclinical and clinical trials.

KW - animal model

KW - dopamine agonist

KW - meta-analysis

KW - study quality

KW - systematic review

UR - http://www.scopus.com/inward/record.url?scp=79957948408&partnerID=8YFLogxK

UR - https://www.sciencedirect.com/journal/parkinsonism-and-related-disorders

U2 - 10.1016/j.parkreldis.2011.02.010

DO - 10.1016/j.parkreldis.2011.02.010

M3 - Review article

VL - 17

SP - 313

EP - 320

JO - Parkinsonism and Related Disorders

JF - Parkinsonism and Related Disorders

SN - 1353-8020

IS - 5

ER -